Source: http://www.google.co.uk/patents/US9402971
Timestamp: 2017-11-24 07:40:02
Document Index: 125528259

Matched Legal Cases: ['Application No. 201080030290', 'Application No. 2012', 'Application No. 14188364', 'Application No. 14188370', 'Application No. 2009', 'Application No. 07752999']

Patent US9402971 - Minimally invasive lung volume reduction devices, methods, and systems - Google Patents
A lung volume reduction system is disclosed comprising an implantable device adapted to be delivered to a lung airway of a patient in a delivery configuration and to change to a deployed configuration to bend the lung airway. The invention also discloses a method of bending a lung airway of a patient...http://www.google.co.uk/patents/US9402971?utm_source=gb-gplus-sharePatent US9402971 - Minimally invasive lung volume reduction devices, methods, and systems
Publication number US9402971 B2
Application number US 14/162,124
Also published as CA2645664A1, CA2645664C, DE202007019683U1, EP1998713A2, EP1998713A4, EP1998713B1, EP2842501A1, EP3143962A1, EP3167821A1, US8142455, US8157823, US8157837, US8282660, US8668707, US8932310, US9782558, US20070221230, US20090012626, US20090076622, US20090076623, US20130102887, US20130217956, US20140371705, US20150080934, WO2007106495A2, WO2007106495A3
Publication number 14162124, 162124, US 9402971 B2, US 9402971B2, US-B2-9402971, US9402971 B2, US9402971B2
Patent Citations (485), Non-Patent Citations (31), Classifications (48), Legal Events (2)
US 9402971 B2
1. An implant for deployment within an airway of a lung of a patient for treating the lung of the patient, the implant comprising:
a first portion having a first bearing surface and defining a first local axis, the first portion of the implant configured to engage a first portion of the airway with the first bearing surface; and
the implant further comprising a second portion coupled to the first portion of the implant, the second portion of the implant having a second bearing surface and defining a second local axis, the second portion of the implant configured to engage a second portion of the airway with the second bearing surface, the second portion of the airway being axially spaced apart from the first portion of the airway;
wherein, in a deployed configuration within the lung, the first portion of the implant presses against the first portion of the airway in a direction lateral to the first local axis and toward the second portion of the implant, and the second portion of the implant presses against the second portion of the airway in a direction lateral to the second local axis and toward the first portion of the implant, thereby compressing lung tissue between the first and second portions of the implant.
2. The implant of claim 1, further comprising a third portion having a third bearing surface and defining a third local axis, the third portion configured to engage the airway with the third bearing surface; and in the deployed configuration within the lung, the third portion presses against the airway in a direction lateral to the third local axis and toward the first portion of the implant and the second portion of the implant, thereby compressing lung tissue between the first, second, and third portions of the implant.
3. The implant of claim 2, further comprising a fourth portion having a fourth bearing surface and defining a fourth local axis, the fourth portion configured to engage the airway with the fourth bearing surface; and in the deployed configuration within the lung, the fourth portion presses against the airway in a direction lateral to the fourth local axis and toward the first, second, and third portions of the implant, thereby compressing lung tissue between the first, second, third, fourth portions of the implant.
4. The implant of claim 3, wherein the first, second, third, and fourth local axes are parallel to each other.
5. The implant of claim 1, further comprising an anchor for anchoring the implant within the airway of the lung.
6. The implant of claim 1, wherein the implant is loaded with a therapeutic drug for release during implant deployment within the airway of the lung.
7. The implant of claim 6, wherein the implant comprises a polymer material and wherein the polymer material regulates a release of the therapeutic drug.
8. The implant of claim 7, wherein the therapeutic drug reduces the rate of wound healing, tissue remodeling, inflammation, generation of granular tissue or a combination of these.
9. An implant for deployment within an airway of a lung of a patient for treating the lung of the patient, the implant comprising:
the elongate body configured to transition between a delivery configuration and a deployed configuration; and
wherein the deployed configuration of the elongate body exerts force on the airway to fold a first portion of the airway of the lung toward a second portion of the airway that is axially spaced apart from the first portion of the airway for locally compressing the lung; and
wherein the elongate body is configured to elute a therapeutic drug.
10. The implant of claim 9, wherein the therapeutic drug is configured to locally reduce a wound healing rate.
11. The implant of claim 9, wherein the therapeutic drug is configured to locally reduce tissue remodeling.
12. The implant of claim 9, wherein the therapeutic drug is configured to locally reduce inflammation.
13. The implant of claim 9, wherein the therapeutic drug is configured to reduce granular tissue formation.
14. The implant of claim 9, wherein the therapeutic drug is configured to reduce hyperplasia.
15. The implant of claim 9, wherein the elongate body comprises a polymer material and wherein the polymer material regulates a release of the therapeutic drug.
16. A method for treating a patient having a lung with an airway, the method comprising:
deploying a lung implant to the airway of the lung, the implant comprising an elongate body having a proximal end and a distal end;
wherein the elongate body of the deployed lung implant folds a first portion of the airway of the lung toward a second portion of the airway that is axially spaced apart from the first portion of the airway; and
wherein the elongate body of the lung implant is configured to elute a therapeutic drug.
17. The method of claim 16, wherein the therapeutic drug released by the elongate body is configured to locally reduce a wound healing rate.
18. The method of claim 16, wherein the therapeutic drug released by the elongate body is configured to locally reduce tissue remodeling.
19. The method of claim 16, wherein the therapeutic drug released by the elongate body is configured to locally reduce inflammation.
20. The method of claim 16, wherein the therapeutic drug released by the elongate body is configured to reduce granular tissue formation.
21. The method of claim 16, wherein the therapeutic drug released by the elongate body is configured to reduce hyperplasia.
22. The method of claim 16, wherein the elongate body of the lung implant comprises a polymer material and wherein the polymer material regulates a release of the therapeutic drug.
The present application is a continuation of U.S. Ser. No. 13/618,986 filed Sep. 14, 2012 (now U.S. Pat. No. 8,668,707); which application is a continuation of Ser. No. 12/167,167 filed Jul. 2, 2008 (now U.S. Pat. No. 8,282,660); which is a continuation of PCT Patent Appln. No. PCT/US2007/006339 filed on Mar. 13, 2007 which claims the benefit of US Provisional Appln. Nos. 60/884,804 filed Jan. 12, 2007 and 60/885,305 filed Jan. 17, 2007 and is a continuation-in-part of Ser. No. 11/422,047 filed Jun. 2, 2006 (now U.S. Pat. No. 8,157,837); which claims the benefit of US Provisional Appln. Nos. 60/743,471 filed Mar. 13, 2006. The disclosures, all of which are incorporated herein by reference in their entirety for all purposes.
Suitable materials for use in constructing the implant, delivery or retrieval systems include materials selected from: metals (stainless steel, nickel-titanium alloy (Nitinol), titanium); polymers (durable and bioabsorbable); ultrahigh molecular weight polyethylene (UHMWPE), polycarbonate, silicone, urethane, Teflon® (available from DuPont), fluoropolymers, Poly (d, 1-lactic-co-glycolic acid), poly(glycolic acid caprolactone), [rho]oly(lactide co-glycolides), as well as any other material that would be considered suitable by a person of skill in the art. Other materials include polymers (nylon, Pebax®, polyetheretherketone (PEEK), polycarbonate, Acrylonitrile Butadiene Styrene (ABS), high density polyethyelene, low density polyethylene, polypropylene, polyimide, urethane, polyethylene, and terephthalate), as well as any other material that would be considered suitable by a person of skill in the art. One or more materials can be employed in any of the embodiments described.
FIG. 3 illustrates the use of a lung volume reduction delivery device 80 for delivering a lung volume reduction device comprising an ‘implantable device with the bronchoscope 50. The lung volume reduction system, as described in further detail below, is adapted and configured to be delivered to a lung airway of a patient in a delivered configuration and then changed to a deployed configuration. By deploying the device, tension can be applied to the surrounding tissue which can facilitate restoration of the elastic recoil of the lung. The device is designed to be used by an interventionalist or surgeon.
FIGS. 35A-C illustrates the process of implanting the device within a lung. As is evidence, the device 2810 is advanced is a configuration where the device adapts to the anatomy of the lungs through the airways and into, for example, the bronchioles until it reaches a desired location relative to the damaged tissue 32. The device is then activated by engaging the actuation device, causing the device to curve and pull the lung tissue toward the activated device (see, FIG. 35B). The device continues to be activated until the lung tissue is withdrawn a desired amount, such as depicted in FIG. 35C. As will be appreciated by those skilled in the art, withdrawing the tissue can be achieved by, for example, curving and compressing a target section of lung tissue upon deployment of one of the configurable devices disclosed herein. Once activated sufficiently, the deployment device is withdrawn from the lung cavity.
Polymers and metals used to make the implant and delivery system should be coated with materials to prevent the formation and growth of granular tissue, scar tissue and mucus. Many of the drugs used with stent products to arrest hyperplasia of smooth muscle cells in blood vessels after deploying metallic stents will work very well for these devices. Slow release drug eluting polymers or solvents may be used to regulate the release of drugs that include any substance capable of exerting a therapeutic or prophylactic effect for a patient. For example, the drug could be designed to inhibit the activity of smooth muscle cells. It can be directed at inhibiting abnormal or inappropriate migration and/or proliferation of smooth muscle cells to inhibit tissue mass buildup. The drug may include small molecule drugs, peptides or proteins. Examples of drugs include antiproliferative substances such as actinomycin D, or derivatives and analogs thereof (manufactured by Sigma-Aldrich of Milwaukee, Wis., or COSMEGEN available from Merck). Synonyms of actinomycin D include dactinomycin, actinomycin IV, actinomycin1, actinomycin X1, and actinomycin C1. The active agent can also fall under the genus of antineoplastic, anti-inflammatory, antiplatelet, anticoagulant, antifibrin, antithrombin, antimitotic, antibiotic, antiallergic and antioxidant substances. Examples of such antineoplastics and/or antimitotics include paclitaxel (e.g. TAXOL® by Bristol-Myers Squibb Co. of Stamford, Conn.), docetaxel (e.g. Taxotere®, from Aventis S. A. of Frankfurt, Germany) methotrexate, azathioprine, vincristine, vinblastine, fluorouracil, doxorubicin hydrochloride (e.g. Adriamycin® from Pharmacia & Upjohn of Peapack N.J.), and mitomycin (e.g. Mutamycin® from Bristol-Myers Squibb). Examples of such antiplatelets, anticoagulants, antifibrin, and antithrombins include sodium heparin, low molecular weight heparins, heparinoids, hirudin, argatroban, forskolin, vapiprost, prostacyclin and prostacyclin analogues, dextran, D-phe-pro-arg-chloromethylketone (synthetic antithrombin), dipyridamole, glycoprotein Hh/IIIa platelet membrane receptor antagonist antibody, recombinant hirudin, and thrombin inhibitors such as Angiomax™ (Biogen, Inc. of Cambridge, Mass.). Examples of such cytostatic or antiproliferative agents include angiopeptin, angiotensin converting enzyme inhibitors such as captopril (e.g. Capoten® and Capozide® from Bristol-Myers Squibb), cilazapril or Hsinopril (e.g. Prinivil® and Prinzide® from Merck & Co., Inc. of Whitehouse Station, N.J.); calcium channel blockers (such as nifedipine), colchicine, fibroblast growth factor (FGF) antagonists, fish oil (omega 3-fatty acid), histamine antagonists, lovastatin (an inhibitor of HMG-CoA reductase, a cholesterol lowering drug, brand name Mevacor® from Merck & Co.), monoclonal antibodies (such as those specific for Platelet-Derived Growth Factor (PDGF) receptors), nitroprusside, phosphodiesterase inhibitors, prostaglandin inhibitors, suramin, serotonin blockers, steroids, thioprotease inhibitors, triazolopyrimidine (a PDGF antagonist), and nitric oxide. An example of an antiallergic agent is permirolast potassium. Other therapeutic substances or agents which jtnay be appropriate include alpha-interferon, genetically engineered epithelial cells, tacrolimus, dexamethasone, and rapamycin and structural derivatives or functional analogs thereof, such as 40-O-(2-hydroxy)ethyl-rapamycin (known by the trade name of EVEROLIMUS available from Novartis of New York, N. Y.), 40-O-(3-hydroxy)propyl-rapamycin, 40-O-[2-(2-hydroxy)ethoxy]ethyl-rapamycin, and 40-O-tetrazole-rapamycin.
3 English Translation of Office Action for corresponding Chinese Application No. 201080030290.4 mailed on Jan. 26, 2014, 11 pages.
4 English Translation of Office Action for corresponding Japanese Application No. 2012-511968 mailed on Nov. 21, 2013, 5 pages.
5 Extended European Search Report for corresponding European Patent Application No. 14188364.5 dated May 29, 2015, 12 pages.
6 Extended European Search Report for corresponding European Patent Application No. 14188370.2 dated Jan. 29, 2015, 10 pages.
7 Hermanson, Greg T. Bioconjugate Techniques. San Diego: Academic Press, Inc. 1996. (Table of contents only).
8 International Search Report and Written Opinion of PCT Application No. PCT/US2009/056839, mailed on Jan. 4, 2010, 15 pages total.
9 International Search Report and Written Opinion of PCT Application No. PCT/US2010/035297, mailed Jul. 20, 2010, 14 pages total.
10 International Search Report of PCT Application No. PCT/US07/06339, dated May 14, 2008, 5 pages total.
11 International Written Opinion of PCT Application No. PCT/US07/06339, dated May 21, 2008, 12 pages total.
12 Lam, et al. X-Ray Diagnosis: A Physician's Approach. Singapore: Springer. 1998. (Table of contents only).
13 O'Brien et al. "Improvements in Lung Function, Exercise, and Quality of Life in Hypercapnic COPD Patients After Lung Volume Reduction Surgery". Chest 115 (1999): 75-84.
14 Office Action for Japanese Patent Application No. 2009-500440, May 11, 2012, 3 pages.
15 Quint et al. "Diaphragmetic Shape Change After Lung Volume Reduction Surgery". Journal of Thoracic Imaging 16 (2001):149-155.
16 Rowe, et al. Handbook of Pharmaceutical Excipients. 4th Edition. London: Pharmaceutical Press. 2003. (Table of contents only).
17 Slone, et al. Body CT: A Practical Approach. New York: McGraw-Hill. 2000. (Table of contents only).
18 Stout, et al. X-Ray Structure Determination: A Practical Guide. 2nd Edition. New York: John Wiley & Sons. 1989. (Table of contents only).
19 Supplementary European Search Report of EP Application No. 07752999.8, mailed Sep. 22, 2009, 12 pages total.
20 The United States Pharmacopeia. 29th Revision. 2006. The United States Pharmacopeia Convention. Rockville, MD. (Table of contents only).
21 U.S. Appl. No. 14/134,977, filed Dec. 19, 2013 by Aronson et al. (Unpublished.).
22 U.S. Appl. No. 14/225,892, filed Mar. 26, 2014 by Mathis et al. (Unpublished.).
23 U.S. Appl. No. 14/260,644, filed Apr. 24, 2014 by Mathis et al. (Unpublished.).
24 U.S. Appl. No. 14/453,372, filed Aug. 6, 2014 by Thompson et al. (Unpublished.).
25 U.S. Appl. No. 60/885,305, filed Jan. 17, 2007; first named inventor: David Thompson.
26 US Notice of Allowance of U.S. Appl. No. 12/167,167 to Thompson et al. mailed Jun. 12, 2012, 8 pages.
27 US Notice of Allowance of U.S. Appl. No. 13/618,986 to Thompson et al. mailed Oct. 23, 2013, 9 pages.
28 US Office Action of U.S. Appl. No. 12/167,167 to Thompson et al. mailed Aug. 8, 2011, 9 pages.
29 US Office Action of U.S. Appl. No. 13/618,986 to Thompson et al. mailed Mar. 28, 2013, 5 pages.
30 Wikipedia, "Medical Ventilator", downloaded from Internet http://en/wikipedia.org/w/index.php?title+Medical-vntilator&printalbe=yes on Jan. 16, 2015, 5 pages.
31 Yusen et al. "A Prospective Evaluation of Lung Volume Reduction Surgery in 200 Consecutive Patients." Chest 123 (2003):1026-1037.
International Classification A61B6/00, A61B1/018, A61B17/00, A61B6/12, A61M16/04, A61B5/06, A61M37/00, A61B17/08, A61B6/03, A61B17/12, A61B1/267, A61F2/04, A61B1/04, A61M16/20
Cooperative Classification A61M16/0833, A61F2002/046, A61M37/0069, A61B1/04, A61B2017/00867, A61B17/12131, A61B17/00234, A61B6/12, A61B2017/12054, A61M16/0406, A61B17/12031, A61B2017/00477, A61B17/1214, A61B2017/00809, A61B90/00, A61B17/12172, A61B90/02, A61F2002/043, A61B1/018, A61M2205/0266, A61B17/12022, A61M16/208, A61M2205/32, A61B6/485, A61B17/12104, A61F2/04, A61B1/2676, A61B17/12145, A61B17/1215, A61M16/04, A61B6/032, A61B5/06, A61B19/00, A61B19/24
Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:MATHIS, MARK L.;REEL/FRAME:034092/0751